British Biotech Defends Decision Not To Disclose DDMAC Letter
British Biotech believes that it was not required to disclose receipt of a Notice of Violation letter from FDA's Division of Drug Marketing, Advertising and Communications, the company said in a May 19 "Circular to Shareholders."
You may also be interested in...
The Securities & Exchange Commission could use its recent ruling that a "cease and desist" settlement appropriately addresses misleading statements made by British Biotech as precedent for corporate disclosure principles.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011